

NanoEHS Landscape (mid 2016)

Greg Lowry


Walter J. Blenko, Sr. Professor of Civil & Environmental Engineering



NSF EF-0830093/1266252

**Carnegie
Mellon
University**

Key Questions to ask about Risk



Exposure



Risk
Characterization

Hazard


- Where do nanomaterials accumulate?
- Who is exposed?
- What form of the NM are we exposed to?
- What exposure concentration is expected?

- What are the acute, chronic, and accumulative effects?
- What is the internal dose?
- How does transformation affect toxicity?

Exposure and Hazard are Inseparable



Exposure x Hazard = Risk



Nanomaterials are Dynamic

- Rates of processes are needed (not equilibrium)

$$\frac{dn_{k_i}}{dt} = \pm \alpha \beta n_i \gamma_j - k_{dissolution} n_k + k_{formation} n_k + k_{transformation} n_k + k_{biouptake} n_k + k_{depuration} n_k$$

- Settling
- Aggregation
- Deposition



- Precipitation
- Bioproduction

- Sulfidation
- Complexation
- Hydroxylation
- Oxidation/ Reduction ...


- Transformation and aggregation affect reactivity, fate, toxicity and persistence
- System properties cannot be ignored


Evidence exists for particle-specific effects

Ag NP toxicity to *C. elegans*




Trophic transfer of nanoparticles occurs






Judy et al., 2011. *Environ. Sci. & Technol.*

Bioaccumulation



Trophic Dilution





Unrine et al. 2012 *Environ. Sci & Technol.*

We can identify and measure some nanomaterials in complex matrices

- Needed for regulatory purposes
- Needed for determining dose
- Improves mechanistic knowledge

SP-ICP-MS



engineered CeO_2 NP




natural Ce-mineral




Stegemeier et al., 2015 *ES&T* 49 (14) 8451

We have nanomaterial environmental fate and exposure models

- Determined key parameters describing ENM behaviors
- Second generation of models emerging
- Sign of maturing field




Keller & Lazareva *Environ. Sci. Technol. Lett.* 2014, 1, 65–70



Dale et al. 2015 *ES&T* 49 (12), pp 7285

We can collect and share data for nanoEHS

- Important for read across



Active projects throughout US & EU

United States Environmental Protection Agency
NBI Knowledgebase
NANOMATERIALREGISTRY
rivm
National Institute for Public Health and the Environment
NANOREG ProSafe
NanoFASE
Serenade


Regulation of Nanomaterials is Advancing

- Adapting existing regulatory programs to include nanomaterials
 - ◉ TSCA New chemical review
 - ◉ REACH Registration
 - ◉ EU Cosmetics directive
- Labeling and Information Disclosure
 - ◉ Proposed TSCA reporting and recordkeeping rule
 - ◉ European registries
- International Cooperation
 - ◉ Canada-U.S. regulatory cooperation council
 - ◉ OECD Working party on manufactured nanomaterials


Where is nanoEHS Heading?

- “Realism”
 - Relevant exposure scenarios (functional assays)
 - Chronic low dose studies
 - Use of “transformed” materials in testing
- Optimizing Benefit-Risk Ratio (“Safe by design”)
 - Leveraging nanoEHS knowledge for effective and safe applications of nanomaterials
 - Environmental applications (water treatment, remediation)
- Categorization (groupings) of nanomaterials

“Realism”




Dosing Strategy




- Incorporating “realism”
- Using relevant exposure scenarios/routes
- Chronic vs. acute exposures





Functional Assays



- Measurement in **prescribed system**
- Quantifies a meaningful process for exposure, hazard or both
- Provides *rate constants* for exposure and hazard models



Optimizing Benefit-Risk Ratio (“Safe by Design”)




Dissolution



Same band gap

Nanomaterial Categorization and Read-Across



ECETOC grouping
From Wendel Wohlleben

Some Important Gaps in Understanding

- No “accepted” testing protocols for nanoEHS
 - “translational roadmap” for exposure assessment
 - Validated bioassays for hazard and dosimetry metrics needed
- Models require further evolution
 - Lack of *rate* data to parameterize and validate models
 - Improve measurements in biological/environments media
 - Need sources of emissions
- Chronic low dose exposures not well studied
- Data and metadata standards needed for nanoinformatics
- Exposures during “use phase” are unknown
- Methods to quantify benefits of nanotechnology are lacking
- Effectiveness of public and private governance mechanisms
- “Next-generation” materials are not being addressed

Exposures along the Lifecycle

Manufacturing



Use Phase



End of Life



Workplace exposure



Exposure Potential??






Research is prioritized



NIOSH
Nanotechnology
Strategic Plan for
2013-2016

Guidance Documents



NIOSH work produces results:

Safe practices protect workers and result in business success and public trust.


Economic growth will come from responsible advancements in manufacturing.

Partnerships with the private sector are key to the NIOSH success story. NIOSH is recognized by stakeholders as the “**most trusted and collaborative**” agency.


Research is reported



NIOSH
Nanotechnology
Progress Report for
2007-2011





Dosimetry is Challenging



Dosimetry models

Harnessing and Quantifying the Benefits of Nanotechnology

Ashby Diagrams for Nano?



- Energy
- Carbon sequestration
- Sustainable agriculture
- Clean water
- Restore/improve urban infrastructure
- Better medicines

From Nanomaterials to Nanomachines!




Fig. 3 Schematic showing the ever-expanding space of nanomaterial conjugation and the resulting permutations of nanomaterials.

Questions to Consider in Breakouts

- Are there gaps in the draft goals and objectives? Are there objectives no longer needed?
- What will be the new/hot areas of research or challenges in the next 5-10 years?
- Outside of additional funding, what can the Federal Government do to support activities or address challenges in the areas above?
- How will we know when the nanotechnology enterprise is successful for NanoEHS? How do we measure this?
- What progress has been made in understanding the ethical, legal, and societal implications of nanotechnology? How has that progress been communicated?

NanoEHS Panel



- Brian Thrall
 - Pacific Northwest National Laboratory
 - nanomaterial cellular interactions



- Matt Hull
 - Virginia Tech (ICTAS, VTSuN, NanoSafe Inc.)
 - nanomaterial environmental fate/effects and nanoinformatics



- Debbie Kaiser
 - NIST
 - materials science, measurement and standards



- Timothy Malloy
 - UCLA
 - Environmental regulation and policy